子宫内膜癌的二线治疗：对更好治疗方案的需求。 - Suppr

Suppr

超能文献

Second-Line Therapy for Endometrial Cancer: The Need for Better Options.

作者信息

Fleming Gini F

机构信息

University of Chicago, Chicago, IL

出版信息

J Clin Oncol. 2015 Nov 1;33(31):3535-40. doi: 10.1200/JCO.2015.61.7225. Epub 2015 Jul 20.

DOI:10.1200/JCO.2015.61.7225

PMID:26195695

Abstract

摘要

相似文献

Second-Line Therapy for Endometrial Cancer: The Need for Better Options.

J Clin Oncol. 2015 Nov 1;33(31):3535-40. doi: 10.1200/JCO.2015.61.7225. Epub 2015 Jul 20.

Effectiveness of gabapentin pharmacotherapy in chemotherapy-induced peripheral neuropathy.

Ginekol Pol. 2018;89(4):200-4. doi: 10.5603/GP.a2018.0034.

Prolonged remission of endometrial cancer with paclitaxel and carboplatin.

Anticancer Drugs. 1998 Mar;9(3):283-5. doi: 10.1097/00001813-199803000-00011.

Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma.

J Cancer Res Clin Oncol. 2005 Sep;131(9):581-4. doi: 10.1007/s00432-005-0676-x. Epub 2005 Oct 20.

Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome.

Dis Colon Rectum. 2004 Nov;47(11):1798-807. doi: 10.1007/s10350-004-0681-1.

Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.

Gynecol Oncol. 2005 Mar;96(3):610-5. doi: 10.1016/j.ygyno.2004.11.024.

Complications following postoperative combined radiation and chemotherapy in adenocarcinoma of the rectum and rectosigmoid. A randomized trial that failed.

Cancer. 1984 Dec 1;54(11):2363-6. doi: 10.1002/1097-0142(19841201)54:11<2363::aid-cncr2820541110>3.0.co;2-u.

[Evaluation of paclitaxel and carboplatin in patients with endometrial cancer].

Gan To Kagaku Ryoho. 2000 Feb;27(2):257-62.

A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma.

Ann Oncol. 2009 Nov;20(11):1787-93. doi: 10.1093/annonc/mdp193. Epub 2009 Jun 19.

Tumor lysis syndrome associated with carboplatin and paclitaxel in a woman with recurrent endometrial cancer.

Int J Gynaecol Obstet. 2010 Jun;109(3):254. doi: 10.1016/j.ijgo.2010.02.005. Epub 2010 Apr 1.

引用本文的文献

Advancing endometrial cancer treatment: exploring immunotherapy and tyrosine kinase inhibitors through clinical cases.

Drugs Context. 2025 Jun 24;14. doi: 10.7573/dic.2025-4-4. eCollection 2025.

Lenvatinib plus pembrolizumab compared to carboplatin plus paclitaxel for carboplatin and paclitaxel pretreated, recurrent, or advanced endometrial cancer.

BMC Med. 2025 Mar 14;23(1):160. doi: 10.1186/s12916-025-03989-0.

Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial.

Nat Commun. 2025 Feb 20;16(1):1821. doi: 10.1038/s41467-025-56914-7.

Treatment Strategies for Advanced Endometrial Cancer According to Molecular Classification.

Int J Mol Sci. 2024 Oct 24;25(21):11448. doi: 10.3390/ijms252111448.

Lenvatinib Plus Pembrolizumab versus Doxorubicin for Advanced or Recurrent Endometrial Cancer with Short Treatment-Free Intervals Following First-Line Carboplatin Plus Paclitaxel.

J Clin Med. 2024 Sep 24;13(19):5670. doi: 10.3390/jcm13195670.

Lenvatinib and pembrolizumab versus platinum doublet chemotherapy as second-line therapy for advanced or recurrent endometrial cancer.

Obstet Gynecol Sci. 2024 Nov;67(6):534-540. doi: 10.5468/ogs.24075. Epub 2024 Sep 27.

Immunotherapy plus chemotherapy in patients with advanced endometrial cancer: a cost-effectiveness analysis.

J Gynecol Oncol. 2025 Jan;36(1):e6. doi: 10.3802/jgo.2025.36.e6. Epub 2024 Jun 3.

A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).

Gynecol Oncol. 2024 Mar;182:75-81. doi: 10.1016/j.ygyno.2023.12.028. Epub 2024 Jan 22.

Radiogenomics for predicting microsatellite instability status and PD-L1 expression with machine learning in endometrial cancers: A multicenter study.

Heliyon. 2023 Dec 1;9(12):e23166. doi: 10.1016/j.heliyon.2023.e23166. eCollection 2023 Dec.

Exposure to select PFAS and PFAS mixtures alters response to platinum-based chemotherapy in endometrial cancer cell lines.

Environ Health. 2023 Dec 14;22(1):87. doi: 10.1186/s12940-023-01034-2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验